Pompe Disease Treatment Market Forecast – Tracking Long-Term Growth
Forecast projections indicate continued expansion of the Pompe Disease Treatment Market over the coming decade. For example, one source projects growth from USD 1.14 billion in 2023 to USD 1.54 billion by 2032, a CAGR of around 3.3%, while others forecast a climb from USD 1.50 billion (2024) to USD 1.95 billion (2030) at 4.4% CAGR. More aggressive estimates see the market reaching over USD 2.7 billion by 2030 at 7.3% CAGR. These forecasts, compiled in the Pompe Disease Treatment Market forecast, reflect how tablets, combination ERTs, and gene therapies could fuel sustained growth—especially with newborn screening and favorable policy landscapes accelerating patient detection.
Forecast scenarios vary by modality: ERT remains dominant, but oral agents and gene-based platforms are gaining share. Clinical success of therapies like cipaglucosidase alfa with miglustat (approved in the EU and US in 2023) and licensure of avalglucosidase alfa (Nexviazyme) are key catalysts. Additionally, policies enabling orphan drug incentives and value-based payment models support market expansion. Taken together, the Pompe Disease Treatment Market forecast paints an evolving picture: stable at present, with accelerated growth expected as innovation and patient identification improve.
FAQQ1: What growth range is expected?A1: Estimates range from modest ~3% to robust ~7% CAGR, depending on modality uptake and geographic expansion.Q2: What will shape future growth?A2: New therapies, expanded screening, and supportive reimbursement models.